Level of aurathrenomedullin in chronic heart failure of ischemic genesis: associations with clinical manifestations
https://doi.org/10.20538/1682-0363-2019-3-81-89
Abstract
Objective. To identify and evaluate the relationship between the level of proadrenomedullin and clinical and anamnestic data of patients with chronic heart failure of ischemic genesis.
Materials and methods. 240 men with chronic forms of coronary heart disease (mean age 55.9 [43; 63] years) and past Q-forming myocardial infarction were examined. Of these, 110 patients had chronic heart failure and preserved left ventricular ejection fraction (group 1) and 130 patients had chronic heart failure and dilatation with a low left ventricular ejection fraction (group 2). In all patients the MR-proADM level in the blood serum was determined.
Results. In the control group, the level of MR-proADM was 0.49 [0.18; 0.58] nmol /l. In the meantime, it was statistically significantly higher in the studied groups of patients than in the control group (p < 0.001 and p < 0.001, respectively). And in the group of patients with chronic heart failure and dilatation with a low left ventricular ejection fraction, it was statistically significantly higher than in the group of patients with chronic heart failure and preserved left ventricular ejection fraction (1.72 [1.56; 1.98] nmol/l and 0.89 [0.51; 1.35] nmol/l, respectively, p < 0.038). The study demonstrated the presence of statistically significant associations between the level of MR-proADM and the severity of chronic heart failure and exertional angina pectoris as well as between the presence of a constant form of atrial fibrillation and the levels of systolic and diastolic blood pressure.
Conclusion. MR-proADM is a new promising marker, which will be possible to use as a diagnostic standard for assessing the effectiveness of treatment of cardiac patients.
About the Author
E. I. Myasoedova
Astrakhan State Medical University
Russian Federation
Russian Federation
PhD, Senior Laboratory Assistant, Division of Internal Diseases,
121, Bakinskaya Str., Astrakhan, 414000
References
1. Saygitov R.T., Chulok A.A. Cardiovascular diseases in the context of social and economic priorities of the long-term development of Russia. Bulletin of the Russian Academy of Medical Sciences. 2015; 3: 286–299 (in Russ.). DOI: 10.15690/vramn.v70i3.1324.
2. Kontsevaya A.V., Drapkina O.M., Badanova Yu.A., Imaeva A.E., Suvorova E.I., Khudyakov M.B. Economic damage from cardiovascular diseases in the Russian Federation in 2016. Rational Pharmacotherapy in Cardiology. 2018; 14 (2): 156–166 (in Russ.). DOI: 10.20996/1819-6446-201814-2-156-166.
3. Lupanov V.P. Stable coronary heart disease: pathogenesis, clinical diagnosis and classification. (Lecture for doctors). Therapist. 2017; 9: 34–40 (in Russ.).
4. Khazov V.S. General theoretical and pathophysiological aspects of the etiology and pathogenesis of coronary artery disease from system positions. Archive of Internal Medicine. 2015; 21 (1): 46–53 (in Russ.). DOI: 10.20514/2226-6704-2015-0-1-46-53.
5. Lyamina N.P., Karpova E.S., Kotel’nikova E.V. Markers of myocardial ischemia: pathophysiological substantiation for clinical use. Pathogenesis. 2018; 16 (1): 17–25 (in Russ.). DOI: 10.25557/2310-0435.2018.01.17-25.
6. Gaggin H.K., Januzzi J.L. Jr. Biomarkers and diagnostics in heart failure. Biochim. Biophys. Acta. 2013; 1832 (12): 2442–2450. DOI: 10.1016/j.bbadis.2012.12.014.
7. Medvedeva E.A., Surkova E.A., Limareva L.V., Shchukin Yu.V. Molecular biomarkers in the diagnosis, risk stratification and prediction of heart failure. Russian Journal of Cardiology. 2016; 21 (8): 86– 91 (in Russ.). DOI: 10.15829/1560-4071-2016-8-86-91.
8. Ostrovskiy O.V., Tkacheva V.V., Ostrovskaya V.O. Laboratory markers of myocardial damage in cardiology practice. Poliklinika. 2013; 1–3: 31–36 (in Russ.).
9. Neumann J.T., Tzikas, Funke-Kaiser A., Wilde S., Appelbaum S., Till K. Association of MR-proadrenomedullin with cardiovascular risk factors and subclinical cardiovascular disease. Atherosclerosis. 2013; 228 (2): 451–459. DOI: 10.1016/j.atherosclerosis.2013.03.006.
10. Kitamura K., Kangawa K., Kawamoto M., Ichiki Y., Nakamura S., Matsuo H., Eto T. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem. Biophys. Res. Commun. 1993; 192 (2): 55–560. DOI: 10.1006/bbrc.1993.1451.
11. Liskova Yu.V., Stolbova M.V., Stadnikov A.A. Neuroendocrine markers of chronic heart failure. Modern Problems of Science and Education. 2015; 5: 319 (in Russ.).
12. Lu W.W., Qi Y.F. Cardiovascular effects and pathophysiological significance of adrenomedullin family peptides. Sheng Li Ke Xue Jin Zhan. 2013; 44 (3): 177–182.
13. Karpov Yu.A. Diagnosis and treatment of chronic ischemic heart disease. Cardiac Нerald. 2015; 10 (3): 3–33 (in Russ.).
14. Mareev V.Yu., Fomin I.V., Ageev F.T., Artyunov G.P., Begrambekova Yu.L., Belenkov Yu.N., Vasyuk Yu.A., Galyavich A.S., Garganeeva A.A., Gendlin G.E., Gilyarevskiy S.R., Glezer M.G., Drapkina O.M., Duplyakov D.V., Kobalava Zh.D., Koziolova N.A., Lopatin Yu.M., Mareev Yu.V., Moiseev V.S., Nedoshivin A.O., Perepech N.B., Sitnikova M.Yu., Skibitskiy V.V., Tarlovskaya E.I., Chesnikova A.I., Shlyakhto E.V. Clinical guidelines. Chronic heart failure (CHF). Heart Failure Journal. 2017; 18 (1): 3–40 (in Russ.). DOI: 10.18087/rhfj.2017.1.2346.
15. Dhillon O.S., Khan S.Q., Narayan H.K., Ng K.H., Struck J., Quin P.A., Morgenthaler N.G., Squire I.B., Davies J.E., Bergmann A., Ng L.L. Prognostic value of mid-regional proadrenomedullin levels taken on admission and discharge in non-ST-elevation myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) II study. J. Am. Coll. Cardiol. 2010; 56 (2): 125–133. DOI: 10.1016/j.jacc.2010.01.060.
16. Hay D.L., Walker C.S., Poyner D.R. Adrenomedullin and calcitonin gene-related peptide receptors in endocrine-related cancers: opportunities and challenges. Endocr Relat Cancer. 2011; 18 (1): 1–14.
17. Yamamoto C., Fukuda N., Jumabay M., Saito K., Matsumoto T., Ueno T., Soma M., Matsumoto K., Shimosawa T. Protective effects of statin on cardiac fibrosis and apoptosis in adrenomedullin-knockout mice treated with angiotensin II and high salt loading. Hypertens Res. 2011; 34 (4): 348–353. DOI: 10.1038/hr.2010.243.
18. Nishikimi T., Kuwahara K., Nakagawa Ya., Kangawa K., Nakao K. Adrenomedullin in cardiovascular disease: a useful biomarker, its pathological roles and therapeutic application. Curr Protein Pept. Sci. 2013; 14 (4): 256– 267. DOI: 10.2174/13892037113149990045.
19. Rademaker M.T., Charles C.J., Nicholls M.G., Richards A.M. Haemodynamic, endocrine and renal actions of adrenomedullin 5 in an ovine model of heart failure. Clin. Sci. (Lond.). 2012; 122 (9): 429–437. DOI: 10.1042/CS20110483.
Review
For citations:
Myasoedova E.I. Level of aurathrenomedullin in chronic heart failure of ischemic genesis: associations with clinical manifestations. Bulletin of Siberian Medicine. 2019;18(3):81-89. (In Russ.) https://doi.org/10.20538/1682-0363-2019-3-81-89
Views:
799
Email this article 